For the Inventor, By the Inventor

Enter assignee name

Redwood City, CA, United States of America

Guardant Health, Inc.

USPTO Granted Patents = 153

EPO Patents = 43

Trademarks = 9

Forward Citations = 1,626

Loading Chart...

Loading Chart...

56 inventors (with patents filed for the assignee):

Amirali Talasaz (89 out of 89 patents)

Stefanie Ann Ward Mortimer (60 out of 61 patents)

Helmy A Eltoukhy (60 out of 98 patents)

4. Darya Chudova (34 out of 56 patents)

5. Andrew Kennedy (15 out of 16 patents)

6. Marcin Sikora (14 out of 14 patents)

7. Diana Abdueva (13 out of 20 patents)

8. AmirAli Talasaz (11 out of 19 patents)

9. Catalin Barbacioru (9 out of 15 patents)

10. William J Greenleaf (7 out of 23 patents)

11. Ariel Jaimovich (6 out of 6 patents)

12. Aliaksandr Artsiomenka (6 out of 6 patents)

13. Martina I Lefterova (6 out of 6 patents)

14. Bahram Ghaffarzadeh Kermani (5 out of 30 patents)

15. Elena Helman (4 out of 4 patents)

Core Competencies:

Cancer Detection

Gene Fusion

Cell-Free DNA

Rare Mutations

Nucleic Acid Analysis

Tumor Mutation Burden

Somatic Mutations

Computational Modeling

Microsatellite Instability

Fragmentome Profiling

High Performance Computing

Residual Disease Monitoring

153 patents: Sort by Forward Citations

1. 12770714 - Methods for fragmentome profiling of cell-free nucleic acids (2026-10-20),

2. 12767991 - MICROSATELLITE INSTABILITY DETECTION IN CELL-FREE DNA (2026-10-20),

3. 12767980 - Methods and systems for detecting genetic variants (2026-10-20),

4. 12744128 - Predictive model for determining changes in molecular state (2026-09-22),

5. 12742204 - Sequencing methods with partitioning (2026-09-22),

6. 12735751 - Systems and methods to detect rare mutations and copy number variation (2026-09-15),

7. 12716103 - MICROSATELLITE INSTABILITY DETECTION IN CELL-FREE DNA (2026-08-25),

8. 12716102 - MICROSATELLITE INSTABILITY DETECTION IN CELL-FREE DNA (2026-08-25),

9. 12706179 - Population based treatment recommender using cell free DNA (2026-08-11),

10. 12706178 - Population based treatment recommender using cell free dna (2026-08-11),

11. 12699906 - IDENTIFICATION OF SOMATIC OR GERMLINE ORIGIN FOR CELL-FREE DNA (2026-08-04),

12. 12692554 - Systems and methods to detect rare mutations and copy number variation (2026-07-28),

13. 12692552 - MICROSATELLITE INSTABILITY DETECTION IN CELL-FREE DNA (2026-07-28),

14. 12665050 - Computational modeling of loss of function based on allelic frequency (2026-06-23),

15. 12662697 - Systems and methods to detect rare mutations and copy number variation (2026-06-23),

Company Overview

Guardant Health, Inc. is a pioneering company based in Redwood City, California, specializing in advanced nucleic acid analysis for cancer detection. The organization focuses on innovative technologies that enable the identification of gene fusions, rare mutations, and tumor mutation burden through the analysis of cell-free DNA. By leveraging computational modeling, Guardant Health aims to enhance precision oncology, providing critical insights that support personalized treatment strategies for cancer patients.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

153 Patents

#15 in Redwood City, CA

#571 in California

#2,584 in US

#5,343 in the World

Redwood City, CA, United States of America

Guardant Health, Inc.

Forward Citations = 1,626

56 inventors:

Amirali Talasaz (89 out of 89 patents)

Stefanie Ann Ward Mortimer (60 out of 61 patents)

Helmy A Eltoukhy (60 out of 98 patents)

4. Darya Chudova (34 out of 56 patents)

5. Andrew Kennedy (15 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Guardant Health, Inc.. Retrieved from https://idiyas.com/company/guardant-health

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…